In a study published in Cell Reports Physical Science on Nov. 25, a research team reported the development of an innovative ...
Nearly three decades later, drug makers have developed six approved small interfering RNA (siRNA) therapeutics in the ...
Ractigen's RAG-21, a treatment for ALS linked to mutations in the FUS gene, has been granted orphan drug designation in the U ...
Inspired by the jets of water that squids use to propel themselves through the ocean, an MIT-led team has developed an ...
Ractigen Therapeutics Co. Ltd.’s RAG-21, a novel siRNA therapy targeting the FUS gene, has been awarded orphan drug designation by the FDA for the treatment of amyotrophic lateral sclerosis (ALS).
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
In a study published in Cell Reports Physical Science on Nov. 25, a research team led by Prof. CAI Lintao from the Shenzhen Institutes of Advanced ...
News Medical on MSN6d
Squid-inspired technology could replace needles for medications and vaccinesThe MiDe systems, inspired by squid propulsion, demonstrate effective needle-free drug delivery in the gastrointestinal tract ...
The firm, which made no change to its Outperform rating or $200 price target, says the deal grants access to a very promising and competitive siRNA platform in terms of drug modality, target, and ...
最近，南加州大学的Terrault教授和密西根大学的Lok教授就通过RNAi/ASO沉默RNA技术在慢性乙肝治愈上的潜能方面在Gut杂志发表述评[1]。就现阶段的慢性乙肝治愈，两位教授认为，尽管在接受NAs治疗的慢性乙肝患者中的HBV ...
2024年11月19日，中美瑞康（Ractigen Therapeutics）宣布其自主研发的FUS基因靶向小干扰RNA（siRNA）疗法RAG-21，成功获得美国食品药品监督管理局（FDA）授予的孤儿药资格（Orphan Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback